A Fundamental Shift in Cancer Care

At Aulos, we’re on a journey to revolutionize cancer patient care through the development of pioneering IL-2 therapeutics that we believe will transform the treatment of solid tumor cancers. We’re taking on the toughest challenges that have limited the effectiveness of IL-2 therapies: the ability to shift IL-2 activity toward immune activation and away from immune suppression, and preventing the toxic side effects of interleukin-2, including vascular leak syndrome and pulmonary edema.

LEARN MORE   →

il2-antibody
Aulos inventive scientific approachExplore Our ScienceOur inventive scientific approach is designed to overcome past limitations in IL-2 therapy by combining precision, potency and safety to transform solid tumor treatment.
Learn More
Aulos Bioscience PipelineOur PipelineAU-007, our initial investigational product candidate, achieves what we believe no other IL-2 therapeutic in development does: tipping the balance toward immune activation.
Learn More
Advanced solutions for cancer careAbout UsWe’re working with purpose to help patients live longer, guided by scientific rigor and motivated by a relentless commitment to advance bold medical solutions that change the course of cancer care.
Learn More

Abstracts and Publications

Explore

FEATURE

Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors

Download PDF

Latest News

Recent Posts

View All   →

AU-007: An Investigational Product Candidate

Aulos has initiated the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers. The first expansion cohorts will focus on melanoma and renal cell carcinoma.

 

LEARN MORE   →

AU-007

Our novel therapeutic candidate is designed to exquisitely direct the body’s immune system to kill tumor cells by more safely and effectively unleashing the anti-cancer power of IL-2.

LEARN MORE   →